Moderna, Inc. (MRNA) Stock: Rises as FDA Clears mFLUSIVA for Adults Over 50
TLDR
- Moderna shares gained 3.37% pre-market after the FDA approved mFLUSIVA nationwide.
- The FDA approved mFLUSIVA for all adults aged 50 and older across the U.S. market.
- A 40,805-person Phase 3 trial supported the vaccine’s safety and effectiveness.
- Moderna plans a U.S. launch during the 2026–2027 respiratory virus season nationwide.
- Regulators in Europe, Canada, and Australia are also reviewing Moderna’s mRNA-1010.
Moderna shares gained before Thursday’s opening bell after federal regulators cleared its mRNA influenza vaccine for eligible older adults nationwide. MRNA rose 3.37% to $58.15 after closing 1.29% lower at $56.26 during Wednesday’s session. The approval adds another commercial product and widens Moderna’s respiratory vaccine portfolio in the United States.
FDA Approves mFLUSIVA for Adults Aged 50 and Older
The FDA approved mFLUSIVA for adults aged 50 years and older across the United States. The decision followed unanimous support from the agency’s Vaccines and Related Biological Products Advisory Committee. Moderna now holds approval for four products in its home market after this decision.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
